Type:Tablet
Generic Name:Irbesartan
Manufacturer:Beximco Pharmaceuticals Ltd.
Price:৳5.00
Diabetic nephropathy, Hypertension
May be taken with or without food.
Oral Hypertension Adult: 150 mg once daily, may increase to 300 mg once daily if needed. Patient w/ intravascular volume depletion: Initially, 75 mg once daily. Elderly: >75 yr Initially, 75 mg once daily. Diabetic nephropathy in Type 2 diabetes mellitus Adult: Initially, 75-150 mg once daily, may increase to 300 mg once daily if needed.
Hypertension <6 years: Safety and efficacy not established 6-12 years: 75 mg/day PO initially; not to exceed 150 mg/day >12 years: 150 mg/day PO initially; may be increased to 300 mg/day PO
Renal impairment: Haemodialysis: Initially, 75 mg once daily. Mild-to-severe renal impairment: Dosage adjustment not necessary unless patient is hypovolemic
Hypersensitivity; pregnancy and lactation.
Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy. Lactation: Potential harm to nursing infant; discontinue drug, or do not nurse
>10% Hyperkalemia (19%) 1-10% Dizziness (10%),Upper respiratory tract infection (URTI) (9%),Orthostatic hypotension (5%),Fatigue (4%),Diarrhea (3%),Dyspepsia (2%)
Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D
May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes. Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
